Measurement of deubiquitinating enzyme activity via a suicidal HA-Ub-VS probe.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Methods in molecular biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/978-1-4939-2013-6_14PMID 25348307
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ATM-Dependent Downregulation of USP7/HAUSP by PPM1G Activates p53 Response to DNA Damage

  2012cited by this paper
• Inhibition of proteasome deubiquitinating activity as a new cancer therapy

  2011cited by this paper
• Stressing the Ubiquitin-Proteasome System without 20S Proteolytic Inhibition Selectively Kills Cervical Cancer Cells

  2011cited by this paper
• Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity.

  2011cited by this paper
• Emerging roles of deubiquitinases in cancer‐associated pathways

  2010cited by this paper
• Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival

  2010cited by this paper
• Suppression of the Deubiquitinating Enzyme USP5 Causes the Accumulation of Unanchored Polyubiquitin and the Activation of p53*

  2009cited by this paper
• Reverse the curse--the role of deubiquitination in cell cycle control.

  2008cited by this paper
• Mechanisms, biology and inhibitors of deubiquitinating enzymes.

  2007cited by this paper
• The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2

  2007cited by this paper
• High expression of ubiquitin carboxy‐terminal hydrolase‐L1 and ‐L3 mRNA predicts early recurrence in patients with invasive breast cancer

  2006cited by this paper
• Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases.

  2006cited by this paper
• A genomic and functional inventory of deubiquitinating enzymes.

  2005cited by this paper
• The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications.

  2004cited by this paper
• Conjugation and deconjugation of ubiquitin regulating the destiny of proteins

  2003cited by this paper
• Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system.

  2003cited by this paper
• Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue

  2000cited by this paper
• The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.

  1993cited by this paper

• USP37 Deubiquitinates CDC73 in HPT-JT Syndrome

  2022cites this paper
• USP5-Beclin 1 axis overrides p53-dependent senescence and drives Kras-induced tumorigenicity

  2022cites this paper
• Pharmacological characterization of a novel metal-based proteasome inhibitor Na-AuPT for cancer treatment

  2021cites this paper
• Regulation of Bax-dependent apoptosis by mitochondrial deubiquitinase USP30

  2021cites this paper
• Broad Spectrum Deubiquitinase Inhibition Induces Both Apoptosis and Ferroptosis in Cancer Cells

  2020cites this paper
• Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers

  2020cites this paper
• Discovering proteasomal deubiquitinating enzyme inhibitors for cancer therapy: lessons from rational design, nature and old drug reposition.

  2018cites this paper
• Ubiquitin-specific protease 21 regulating the K48-linked polyubiquitination of NANOG.

  2017cites this paper
• Efficient chemical synthesis for the analogue of ubiquitin-based probe Ub–AMC with native bioactivity

  2016cites this paper